Advanced search
Publication Cover
Scandinavian Journal of Infectious Diseases Volume 31, 1999 - Issue 1
Submit an article Journal homepage
298
Views
58
CrossRef citations to date
0
Altmetric
Research Article

Safety Profile of Meropenem: a Review of Nearly 5,000 Patients Treated with Meropenem

S. Ragnar Norrby, Kathleen M. Gildon
Pages 3-10 | Published online: 08 Jul 2009

  • Bradley JS, Garau J, Lode H, Rolston KVI, Wilson SE, Quinn JP. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents 1999. In press.
  • Lyon JA. Imipenem/cilastatin: the first carbapenem antibiotic. Drug Intell Clin Pharm 1985; 19: 895–9.
  • Calandra G, Lydick E, Carrigan J, Weiss L, Guess H. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988; 84: 911–8.
  • Physicians’ Desk Reference. Montvale, NJ: Medical Economics Company Inc., 1998: 2153–7.
  • Calandra GB, Wang C, Aziz M, Brown KR. The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients. J Antimicrob Chemother 1986; 18 Suppl E: 193–202.
  • Wang C, Calandra GB, Aziz MA, Brown KR. Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience. Rev Infect Dis 1985; 7 Suppl 3: S528–36.
  • Norrby SR, Vandercam B, Louie T, Runde V, Norberg BO, Anniko M, et al. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective randomized multicentre study. Scand J Infect Dis 1987; 52 Suppl: 65–78.
  • Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchinson M, Howarth SJ. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989; 24 Suppl A: 311–20.
  • Harrison MP, Moss SR, Featherstone A, Fowkes AG, Sanders AM, Case DE. The disposition and metabolism of meropenem in laboratory animals and man. J Antimicrob Chemother 1989; 24 Suppl A: 265–77.
  • Kanellakopoulou K, Giamarellou H, Papadothomakos. Chloroyiannis J, Theakou R, Sfikakis P. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 1993; 12: 449–53.
  • Huizinga WK, Warren BL, Baker LW, Valleur P, Pezet DM, Hoogkamp-Korstanjep JAA, Karrau SJ. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother 1995; 36 Suppl A: 179–89.
  • Klugman KP, Dagan R and the Meropenem Meningitis Study Group. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Antimicrob Agents Chemother 1995; 39: 1140–6.
  • Meropenem Study Group of Leuven, London and Nijmegen. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1995; 36: 185–200.
  • Mouton YJ, Beuscart C. Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group. J Antimicrob Chemother 1995; 36 Suppl A: 145–56.
  • Nichols RL, Smith JW, Geckler RW, Wilson SE. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J 1995; 88: 397–404.
  • Colardyn F, Faulkner KL and the Meropenem Serious Infection Study Group. Intravenous meropenem versus imipenem/ cilastatin in the treatment of serious bacterial infections in hospitalised patients. J Antimicrob Chemother 1996; 38: 523–37.
  • Kahan FM, Kropp H, Sundelof JG, Birnbaum J. Thienamycin: development of imipenem-cilastatin. J Antimicrob Chemother 1983; 12 Suppl D: 1–35.
  • Norrby SR, Alestig K, Björnegård B, Burman L, Ferber F, Kahau H, Huber J, Jones K. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrob Agents Chemother 1983; 23: 300–7.
  • Norrby SR, Newell PA, Faulkner KL, Lesky W. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995; 36 Suppl A: 207–23.
  • Cometta A, Calandra T, Gaya H, Zinner SH, de Boch R, Del Farero A, Bucaueve G, Crohaert F, Keru VW, Kelasteriky J, Lauqeuaekeu I, Micozzi A, Padnas A, Paesmans M, Viscoli C, Glauser MP. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996; 40: 1108–15.
  • Eng RH, Munsif AN, Yangco BG, Smith SM, Chmel H. Seizure propensity with imipenem. Arch Intern Med 1989; 149: 1881–3.
  • Wong VK, Wright HT Jr, Ross LA, Mason WH, Inderlied CB, Kim KS. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991; 10: 122–5.
  • Winston DJ, Ho WG, Bruckner DA, Champlin E. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. Ann Intern Med 1991; 115: 849–59.
  • Freifeld AG, Walsh T, Marshall D, Gress J, Steinberg SM, Hathorn J, Rubin M, Jarosiuski P, Gill V, Young RC. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995; 13: 165–76.
  • Shah PM, Heller A, Fuhr HG, Walther F, Halis S, Schaumann R, Bolime A, Jung B, Kuhler A, Lips-Schulte C, Stike W. Empirical monotherapy with meropenem versus imipenem/ cilastatin for febrile episodes in neutropenic patients. Infection 1996; 6: 480–4.
  • Mehtar S, Dewar E, Leaper D, Taylor E. A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalised patients with serious infections. J Antimicrob Chemother 1997; 39: 631–8.
  • Hense J, Uppenkamp M, Meusers P, Brittinger G. Prospective randomized trial of bolus meropenem versus infusion meropenem versus ceftazidime/amikacin as empiric initial therapy for infections and fever of unknown origin in neutropenic patients with hematologic malignancies. The Third International Symposium on Febrile Neutropenia, Brussels, 1997; Abstract 58.
  • De Turck BJG, Diltoer MW, Cornelis PJWW, Maes V, Spapen HPM, Camis F, Huygbeus LP. Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin. J Antimicrob Chemother 1998; 42: 563–4.
  • Nagai K, Shimizu T, Togo A, Takeya M, Yukomizo Y, Matsuishi T, Kato H. Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron. J Antimicrob Chemother 1997; 39: 295–6.
  • Hartenauer U. Efficacy and safety of antiinfective therapy with meropenem in the clinical routine. Antiinfective Drugs & Chemotherapy 1998; Suppl 16: 80.
  • Ciofu O, Jensen T, Pressler T, Johansen HK, Koch C, Høiby N. Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to β-lactam antibiotics. Clin Microbiol Infect 1996; 2: 91–8.
  • Cunha BA. Meropenem in elderly and renally impaired patients: a safety review. Int J Antimicrob Agents 1998; 10: 107–17.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.